Doyle John Brendan

Doyle John Brendan is listed in filings as Chief Financial Officer at Cognition Therapeutics, Inc.. This profile follows SEC Form 4 activity through May 4, 2026, including purchase activity. Recent filings connect the profile to Cognition Therapeutics, Inc. (CGTX). The current snapshot covers public activity from Feb 4, 2025 to May 4, 2026. Reported amounts are shown as $11.0K to $1.7K. The page organizes purchases, sales, issuer links, reported share activity, and filing evidence for review as public disclosure data.